BIT:1BBIO • US10806X1028
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BRIDGEBIO PHARMA INC (1BBIO.MI).
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 9.303M -88.02% | 221.902M 2,285.27% | 502.076M 126.26% | 944.72M 88.16% | 1.645B 74.13% | 2.425B 47.42% | 3.307B 36.37% | 4.128B 24.83% | 4.954B 20.01% | 5.611B 13.26% | 6.049B 7.81% | |
| EBITDA YoY % growth | -592.95M -28.44% | -571.293M 3.65% | -496.63M 13.07% | -265.116M 46.62% | 258.16M 197.38% | 640.03M 147.92% | 639.54M -0.08% | 1.113B 74.03% | 1.592B 43.04% | 2.017B 26.70% | 2.39B 18.49% | |
| EBIT YoY % growth | -599.444M -27.97% | -577.368M 3.68% | -502.064M 13.04% | -274.777M 45.27% | 256.99M 193.53% | 911.06M 254.51% | 1.551B 70.24% | 2.261B 45.78% | 2.851B 26.09% | 3.407B 19.50% | 3.785B 11.09% | |
| Operating Margin | -6,443.56% | -260.19% | -100.00% | -29.09% | 15.62% | 37.57% | 46.90% | 54.77% | 57.55% | 60.72% | 62.57% | |
| EPS YoY % growth | -3.94 -26.69% | -3.09 21.57% | -3.78 -22.33% | -1.88 50.16% | 0.63 133.68% | 3.86 508.75% | 6.74 74.54% | 12.70 88.35% | 12.04 -5.22% | 13.13 9.07% | 12.26 -6.60% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.70 20.28% | -0.56 40.99% | -0.48 49.70% | -0.32 68.43% | -0.26 63.65% | -0.11 81.08% | 0.01 101.28% | 0.13 140.06% | 0.20 180.00% | 0.37 446.15% | 0.58 9,400.00% | 0.79 520.97% |
| Revenue Q2Q % growth | 182.29M 56.29% | 215.34M 94.76% | 241.01M 99.68% | 287.16M 86.25% | 298.66M 63.84% | 346.06M 60.70% | 389.79M 61.73% | 445.9M 55.28% | 525.93M 76.10% | 573.79M 65.81% | 628.48M 61.24% | 683.61M 53.31% |
| EBITDA Q2Q % growth | -110.667M -7.95% | -86.705M 33.75% | -61.977M 53.18% | 6.861M 105.58% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -105.291M -1.43% | -78.37M 41.28% | -62.811M 53.94% | -26.331M 79.50% | -32.062M 69.55% | -11.73M 85.03% | 15.47M 124.63% | 47.226M 279.35% | N/A | N/A | N/A | N/A |
All data in USD
29 analysts have analysed 1BBIO.MI and the average price target is 86.88 EUR. This implies a price increase of 35.26% is expected in the next year compared to the current price of 64.23.
BRIDGEBIO PHARMA INC (1BBIO.MI) will report earnings on 2026-04-30.
The consensus EPS estimate for the next earnings of BRIDGEBIO PHARMA INC (1BBIO.MI) is -0.7 EUR and the consensus revenue estimate is 182.29M EUR.
The consensus rating for BRIDGEBIO PHARMA INC (1BBIO.MI) is 85.5172 / 100 . This indicates that analysts generally have a positive outlook on the stock.